Sunshine Biopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sunshine Biopharma Inc 's ROA in the second quarter of 2026?
Sunshine Biopharma Inc recorded a cumulative net loss of $-6 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -19.18%.

However, within the Healthcare sector 353 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3447, from total ROA ranking in the first quarter of 2026 at 4041.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	5.22 %	-6.75 %	-4.12 %	4.76 %	11.23 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-6	-6	-6	-6
Return On Assets (TTM)	-19.18 %	-20.14 %	-19.6 %	-19.46 %	-20.72 %
SBFM's Total Ranking	# 3447	# 4041	# 3534	# 3597	# 3550
Total Assets (TTM) in million	34	27	29	31	32
Seq. Total Assets Change	23.57 %	-7.11 %	-6.95 %	-1.49 %	9.52 %
Seq. Net Income Change	-	-	-	-	-

SBFM's 5 Years Annual ROA >> Back to SBFM Management Effectiveness >> Compare SBFM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 127
Sector	# 354
Overall	# 3401

Return On Assets Statistics
High	Average	Low
230.88 %	-303.27 %	-1565.82 %
(Mar 31 2014)		(Jun 30 2020)

Financial Statements
Sunshine Biopharma Inc 's Assets	$ 34 million	SBFM's Balance sheet
Sunshine Biopharma Inc 's Income	$ -2 million	Quarterly SBFM's Income Statement
SBFM's Income by Division		See SBFM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-4.12 %	14.46 %	-6.26 %	1192.99 %	110.7 %
Total Assets in million	29	31	27	28	2
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-6	-5	-5	-27	-12
Annual Return On Assets	-20.39 %	-16.8 %	-16.88 %	-93.89 %	-564.54 %

SBFM's 5 Years Annual ROA >> Back to SBFM Management Effectiveness >> Compare SBFM ROA to its Competitors

More Return On Assets Ratios
SBFM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SBFM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SBFM's Competitors
Subscribers only: Roa for Sunshine Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for SBFM's Customers

You may also want to know
SBFM's Roi	SBFM's Inventory Turnover Ratio	SBFM's Growth Rates	SBFM's Dividend Comparisons
	SBFM's Profitability Ratios	SBFM's Asset Turnover Ratio	SBFM's Dividend Growth
SBFM's Roe	SBFM's Valuation Ratios	SBFM's Financial Strength Ratios	SBFM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-02T20:05:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.